Predictive Value of the Naples Prognostic Score for outcomes in Brain Metastases Treated with Gamma Knife

When cancer spreads from its original site to other parts of the body, the brain is a frequent and dangerous destination. For decades, doctors have relied on precise radiation tools like the Gamma Knife to target these secondary tumors without damaging the surrounding healthy tissue. This method delivers a powerful dose of energy directly to the cancer, sparing the rest of the brain and preserving a patient's ability to think and move. However, even with this advanced technology, the outcome varies wildly from one person to the next. Some patients see their tumors shrink significantly and live for years, while others see little improvement or rapid return of the disease. The medical community has long searched for a way to predict who will respond well to treatment and who will not, looking beyond just the size or location of the tumor to find clues hidden within the patient's own body.

Recent science has pointed toward a connection between how a person's body fights inflammation and how well their cancer cells react to radiation. When the immune system is in a state of constant, low-level alarm, it can sometimes help tumors grow and resist treatment. Similarly, if a patient is not getting enough nutrition, their body may struggle to repair itself after the stress of radiation. Researchers have developed a way to measure this balance by looking at four simple blood tests: the ratio of two types of white blood cells, the level of a specific protein made by the liver, and the amount of cholesterol in the blood. By combining these numbers, doctors can create a single score that reflects a patient's overall state of inflammation and nutrition. This score, known as the Naples Prognostic Score, has been used to predict outcomes in other types of cancer, but its value for patients with brain metastases treated with Gamma Knife remained unproven.

A team of researchers set out to test whether this blood-based score could predict the success of Gamma Knife treatment for brain metastases. They looked back at the medical records of 111 patients who had received this treatment between 2019 and 2021. Before the radiation began, the team calculated each patient's score based on their blood work. They then divided the group into three categories: low risk, intermediate risk, and high risk. The low-risk group had the best balance of inflammation and nutrition, while the high-risk group showed signs of significant inflammation and poor nutritional status. The researchers followed these patients closely, checking their brain scans one month after treatment to see if the tumors had shrunk, and continuing to monitor them to see how long they remained free of new cancer growth in the brain.

The results showed a clear pattern. Patients in the low-risk group responded best to the treatment, with nearly three-quarters of them seeing a significant reduction in their tumor size. In contrast, only about half of the patients in the high-risk group achieved this same level of improvement. The difference was not just about how the tumors looked on a scan; it also affected how long patients stayed free of disease progression. The low-risk group went an average of 11 months without their cancer returning or spreading within the brain, while the high-risk group lasted only five months on average. The intermediate group fell right in the middle, with a seven-month average. The study confirmed that this blood score was an independent predictor of success, meaning it provided valuable information even when accounting for other factors like the number of tumors or the patient's general physical health.

Importantly, the researchers found that this score did not predict the safety of the treatment. The rate of side effects, such as bleeding or swelling in the brain, was low and roughly the same across all three groups. Similarly, the patients' ability to think, remember, and focus did not differ based on their score. This suggests that while the blood test can tell doctors who is likely to benefit most from the radiation, it does not indicate who is more likely to suffer from the procedure's side effects. The study also noted that other factors, such as having a large tumor volume or cancer spreading to the lining of the brain, were also linked to poorer outcomes, but the blood score remained a powerful tool on its own.

These findings suggest that a simple blood test taken before treatment could help doctors understand which patients are likely to have a good response to Gamma Knife radiation and which might need additional support or different strategies. The score acts as a window into the patient's internal environment, revealing how their body's inflammation and nutrition levels might influence the cancer's reaction to radiation. While the study was limited by its size and the fact that it looked at past data, the consistency of the results offers a promising new way to personalize care. By identifying patients who are at higher risk of poor outcomes before the first dose of radiation is delivered, doctors can potentially tailor their treatment plans more effectively, ensuring that the right patients receive the right level of care at the right time.